[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529693":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":36,"responsibleParty":57,"collaborators":20,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":20,"enrollmentInfo":69,"targetDuration":20,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Sunnybrook Health Sciences Centre","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Interventional","EXPERIMENTAL","All radiotherapy will be delivered on the MR-linac",[13],"Radiation: MR Linac delivered Radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","MR Linac delivered Radiotherapy","All radiotherapy will be delivered on the MR-linac. The whole prostate will receive 30 Gy in 5 fractions and the dominant lesion plus intra-prostatic margin will receive an isotoxic 45 Gy prescription.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Danny Vesprini, M.D.","PRINCIPAL_INVESTIGATOR",[26,31],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","416-480-4806","4806","Danny.Vesprini@sunnybrook.ca",{"name":32,"role":27,"phone":33,"phoneExt":34,"email":35},"Murtuza Saifuddin, M.S.","416-480-5000","63094","murtuza.saifuddin@sunnybrook.ca",[37],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Toronto","Ontario","M4N 3M5","Canada","CA",{"type":45,"coordinates":46},"Point",[47,48],-79.39864,43.70643,{"lat":48,"lon":47},[51,53,55],{"name":52,"role":27,"phone":28,"phoneExt":29,"email":30},"Dr. Danny Vesprini, MD, FRCPC,",{"name":32,"role":27,"phone":54,"phoneExt":34,"email":35},"4164805000",{"name":56,"role":24,"phone":20,"phoneExt":20,"email":20},"Danny Vesprini, MD, FRCPC",{"type":58,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100529693","pilot-study-of-dose-escalation-in-prostate-radiotherapy-using-the-mr-linac-destination-mrl-100529693",false,"NCT06177093","Pilot Study of Dose Escalation in Prostate Radiotherapy Using the MR-Linac (DESTINATION-MRL)","A Pilot Study of Dose dE-eScalaTion IN prostATe radIOtherapy usiNg the MRL","DESTINATION-MR","Inclusion Criteria:\n\n* Men aged ≥18 years\n* Histological confirmation of prostate adenocarcinoma requiring radical radiotherapy\n* Gleason score 3+3, 3+4 or 4+3 (Grade groups 1, 2 or 3)\n* MRI stage T2 or less (as staged by AJCC TNM 2018)\n* MRI-visible tumour(s) of PIRADS v2 grade 3 or higher on T2 and diffusion-weighted imaging and\u002For dynamic contrast-enhanced imaging (multiparametric MRI or mpMRI) with concordant pathology\n* Tumour nodule visible on MRI occupying \\\u003C50% of prostate on any axial slice and \\\u003C50% prostate volume\n* PSA \\\u003C20 ng\u002Fml prior to starting ADT (if applicable)\n* Short course (\\\u003C 6 months) concurrent androgen deprivation therapy (antiandrogens or LHRH analogues) allowed though not mandated as per the discretion of the treating physician.\n* WHO Performance status 0-2\n* Ability of the participant understand and the willingness to sign a written informed consent form.\n* Ability\u002Fwillingness to comply with the patient reported outcome questionnaires schedule throughout the study.\n\nExclusion Criteria:\n\n* Contraindications to MRI (e.g. pacemaker, potentially mobile metal implant, claustrophobia)\n* IPSS 19 or higher\n* High grade disease (GG3) occult to MRI-defined lesion\n* Post-void residual \\>100 mls, where known\n* Prostate volume \\>90cc\n* Comorbidities which predispose to significant toxicity (e.g. inflammatory bowel disease) or preclude long term follow up\n* Unilateral or bilateral total hip replacement, or other pelvic metalwork which causes artefact on diffusion-weighted imaging\n* Previous pelvic radiotherapy\n* Patients needing \\>6 months of ADT due to disease parameters as per the discretion of the treating physician\n* Previous invasive malignancy within the last 2 years excluding basal or squamous cell carcinomas of the skin, low risk non-muscle invasive bladder cancer (assuming cystoscopic follow up now negative) or small renal masses on surveillance.","MALE","18 Years",{"count":70,"type":71},20,"ESTIMATED","INTERVENTIONAL",[74],"NA","This study is a single centre feasibility trial. The trial will recruit men with intermediate risk localised prostate cancer who will all receive targeted dose (escalated\u002Fde-escalated dose directed by MRI) 5 fraction SBRT to the prostate.\n\nTrial Objectives are:\n\n1. Primary To develop a 5 fraction de-escalated dose SBRT protocol capable of reducing side effects\n2. Secondary\n\n   * To assess levels of acute GU and GI toxicity (CTCAE)\n   * To assess levels of late GU and GI toxicity (CTCAE)\n   * To assess late sexual quality of life (expanded EPIC, IIEF-5)\n   * To assess biochemical relapse-free survival at 2",[77],"Prostate Cancer",[79],"Newly diagnosed intermediate risk localized prostate cancer","2026-05-13",{"date":82,"type":83},"2026-05-15","ACTUAL",{"date":85,"type":83},"2023-12-11",{"date":87,"type":71},"2027-12-01",{"name":5,"class":6},1]